By Ashley Welch
The majority of patients can continue treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) before undergoing elective surgeries, according to new multispecialty guidance from surgeons, anesthesiologists and gastroenterologists.
The recommendation is a reversal of 2023 guidance from the American Society of Anesthesiologists (ASA), which then advised a one-week or one-day break from injectable GLP-1 agents and once-daily oral agents, respectively. That initial